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REQUEST
What is the evidence for the use of sincalide in the treat-
ment and prevention of parenteral nutrition (PN)–associat-
ed gallbladder disease?
RESPONSE
BACKGROUND
PN is a life-saving therapy in patients with intestinal
failure. Its use, however, can be associated with many
complications of metabolic and infectious nature.1 Hepato-
biliary complications including cholestasis, steatosis, bil-
iary sludge, and cholelithiasis mostly occur in patients who
are dependent on PN, while oral or enteral feeding is absent.
Many factors predispose or contribute to PN-associated liver
disease including long duration of PN, prolonged fasting,
lack of bowel motility, short gut syndrome, recurrent sepsis,
overfeeding, and possible nutrient deficiencies.2
Formation of tenacious and hyperviscous bile with pre-
cipitation of cholesterol gallstones and formation of calci-
um bilirubinate crystals in the form of sludge have been re-
ported in PN-dependent patients.3-5 The risk of developing
biliary sludge is directly related to the duration of PN, with
50–100% of patients having some level of sludge forma-
tion within 4–6 weeks of PN therapy.6 Some patients with
gallbladder sludge will also develop cholelithiasis, a com-
mon complication in patients with short bowel syndrome
who have impaired bile flow and disrupted enterohepatic
bile recycling.6-14 Patients with biliary sludge or gallstones
may develop acalculous or calculous cholecystitis and
choledolithiasis where cholecystectomy may be indicat-
ed.15 PN-associated cholestasis (PNAC) is a more severe
liver complication in patients receiving long-term PN.
PNAC can be reversible if PN is discontinued and oral or
enteral nutrition initiated before irreversible liver damage
has occurred. However, jaundice and progressively in-
creasing serum bilirubin levels in long-term PN patients
may indicate advanced liver disease.2 PN-dependent pa-
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tients with short bowel syndrome are at highest risk for de-
veloping end-stage liver disease. In these patients, com-
bined liver and bowel transplantation may be indicated as
a life-saving approach.16
Although the etiology of PN-associated gallbladder dis-
ease is multifactorial, the lack of endogenous cholecys-
tokinin (CCK) secretion is a significant contributing
factor.7-10 CCK is a peptide hormone secreted in the upper
small intestine in response to meals, especially fat.17 CCK
stimulates gallbladder contraction, causes relaxation of the
sphincter of Oddi, inhibits gastric emptying, and increases
intestinal motility. In PN-dependent patients, the lack of
enteral stimulation results in diminished CCK secretion
and reduced bile flow.18-20 Sincalide, also known as chole-
cystokinin– octapeptide, is the synthetic C-terminal oc-
tapeptide fragment of CCK. When administered intra-
venously, sincalide produces the effects of the biologically
active CCK molecule.21,22 Sincalide is commercially avail-
able in parenteral forms for intravenous and intramuscular
administration and is approved for postevacuation chole-
cystography. The recommended sincalide dose for this indi-
cation is 0.02 µg/kg given intravenously, followed by a sec-
ond dose of 0.04 µg/kg if satisfactory effects are not initially
seen.23 Given the actions of sincalide on the gallbladder, the
utility of this agent in the prevention and treatment of PN-as-
sociated gallbladder disease has been investigated.20,24-31 Sin-
calide is a potentially inexpensive therapy to alleviate
PNAC in infants. The average wholesale price $35.17 per
5-µg vial.32
CLINICAL TRIALS
Early animal studies showed that sincalide prevents PN-
associated biliary stasis.24,25 In subsequent animal studies,
sincalide therapy yielded mixed results.26,27 In one investi-
gation, sincalide did not improve bile flow or bile acid se-
cretion in animals that were given PN despite slight im-
provements in liver fibrosis and portal inflammation.26 In
another study, sincalide therapy did not affect the bile salt
profile and did not prevent gallstone formation, despite its
effects on improving bile acid synthesis and output.27
In humans, a preliminary study reported that prophylac-
tic sincalide administration prevents biliary sludge in adults
receiving long-term PN.28 This was a randomized, double-
blind, placebo-controlled trial of patients who received PN
for >3 weeks. Seven patients (mean age ± SEM, 29.7 ± 3.8
y) were treated with sincalide, while 8 matched patients re-
ceived saline placebo. Sincalide 0.05 µg/kg/day was admin-
istered intravenously over 10 minutes. None of the patients
had biliary sludge or gallstones at baseline as confirmed by
ultrasound imaging. Patients in the sincalide and placebo
groups received PN for an average of 60 and 44 days, re-
spectively (p > 0.05). In contrast to the placebo group, ad-
ministration of sincalide significantly increased gallbladder
emptying (58% vs 2% 45 min after the dose; p < 0.02). Af-
ter a mean of 4 weeks of sincalide therapy, 5 (63%) patients
in the placebo group developed biliary sludge, while no pa-
tients allocated to sincalide developed biliary sludge or gall-
stones as evidenced through ultrasound imaging techniques
(p < 0.02). Sincalide was well tolerated. Two patients experi-
enced mild abdominal cramps, and one had increased osto-
my output. 
Another study confirmed the beneficial effects of sin-
calide on gallbladder contraction in normal adult volunteers
and patients receiving PN for >2 weeks.20 Prior to treat-
ment, a 62% increase in gallbladder volume as evidenced
by ultrasound was noted in the 6 PN patients allocated to
receive sincalide. Administration of a single sincalide dose
of 0.045 µg/kg intravenously over 15 minutes caused a
50% and 55% gallbladder contraction (defined as percent
of basal volume) in PN-treated patients and healthy con-
trols, respectively. This response was less than but similar
to the 60% gallbladder contraction observed in the control
group 30 minutes following intake of a high-fat meal.
Forty percent of patients treated with sincalide experienced
nausea, while vomiting and abdominal pain each occurred
in 10% of the study population.
The effects of sincalide were more extensively investi-
gated in children receiving PN. In a study of 8 postopera-
tive infants with PNAC (mean body weight 2030 g, range
800–3700), 4 of whom were born prematurely, adminis-
tration of lyophilized porcine CCK, a molecule similar to
sincalide, caused a rapid decline in serum conjugated
bilirubin levels and the resolution of jaundice and acholic
stools.29 The median duration of PN and conjugated hyper-
bilirubinemia (conjugated bilirubin concentrations >3
mg/dL) with clinical jaundice were 25 and 42 days, re-
spectively. CCK was administered intravenously 3 times
daily in an initial dose of 2 IDU (Ivy dog units)/kg and in-
creased to 4 IDU/kg in the case of refractory symptoms
(conversion between IDU and µg undetermined). In 7 of
the patients, CCK restored bile flow. In these infants,
stools resumed their normal color within 1–3 days, clinical
jaundice resolved within a week, and serum conjugated
bilirubin levels declined over 2 weeks following treatment
with CCK. Biliary sludge or stones initially observed in 3
patients at baseline resolved after restoration of biliary
flow. Adverse effects reported with CCK infusion included
mild abdominal cramps and restlessness. Although the au-
thors advocated that CCK might rapidly reverse cholestasis,
several factors may have influenced their results. Seven pa-
tients were weaned from PN before CCK administration, a
factor that may by itself have contributed to the observed
improvement. Also, one patient did not respond to repeat-
ed CCK administrations and, finally, the study did not have
a control group for comparison of effects. Nevertheless,
the results of this study suggest that CCK may improve the
clinical signs of PNAC. 
Similarly, in a nonrandomized, uncontrolled pilot study
of 11 surgical infants with PNAC (mean gestational age ±
SEM, 30.7 ± 1.8 wk), 9 of whom were born prematurely,
the administration of sincalide caused a reduction in serum
conjugated bilirubin levels.30 Prior to sincalide therapy, pa-
tients received PN for a mean of 107 days. At the time of
sincalide initiation, 5 of the 11 patients were receiving en-
teral feeding and 2 patients were no longer receiving PN.
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Following parenteral administration of sincalide 0.02
µg/kg twice daily for 16–29 days in 3 infants and
0.02–0.32 µg/kg every 8 hours for 3–33 days in 8 infants,
mean conjugated bilirubin concentrations declined from
12.1 ± 1.7 to 9.3 ± 2.2 mg/dL (normal 0–0.2) (p = 0.09).
However, no significant improvement in serum aspartate,
alanine aminotransferase, or alkaline phosphatase levels
was observed. Sincalide was well tolerated. Two infants
had gastrointestinal adverse effects characterized by ab-
dominal pain and feeding intolerance, each of which re-
solved after sincalide was discontinued. 
The results of this study should be interpreted with cau-
tion. Patients whose PN comprised <50% of their nutri-
tional needs responded more favorably than those who
were mostly dependent on PN. As such, enteral feeding
and cessation of PN may have contributed to the improve-
ment in bilirubin levels independent of sincalide therapy.
Also, a statistically significant improvement in hyperbiliru-
binemia was achieved only after 3 nonresponding patients
with liver failure were excluded. This raises the question of
whether sincalide would be beneficial in PN patients with
advanced liver disease. Additionally, the clinical implica-
tions of the minor improvements in conjugated bilirubin
levels appear insignificant, and clinical jaundice persisted
despite sincalide treatment.30
The same group of investigators subsequently complet-
ed a study examining the prophylactic effects of sincalide
in 21 infants with PNAC (mean gestational age ± SD, 31.8
± 5.5 wk, mean age at start of therapy 1.61 ± 0.98 wk,
mean birth weight 1.64 ± 1.0 kg).31 PNAC was defined as
conjugated bilirubin >2 mg/dL. Sincalide was first initiated
at a dose of 0.02 µg/kg twice daily and then increased to
0.04 µg/kg 3 times daily if PN was continued beyond 14
days. Sincalide was discontinued when at least 50% of the
patient’s nutritional intake was provided via the enteral
route. Patients with liver disease were excluded. The con-
trol group included a cohort of infants with PNAC who
were matched by gestational age, diagnosis, and duration
of PN. After the third week of PN, a rapid rise in serum
conjugated bilirubin levels was observed in the control
group, but not in the sincalide group. The incidence of
PNAC was not significantly different between the groups
(p = 0.15). However, the incidence of severe PNAC (de-
fined as conjugated bilirubin >5 mg/dL) was significantly
different between treated and nontreated patients (p =
0.015). The observed improvement in this study, however,
cannot be attributed to sincalide alone, as patients also re-
ceived enteral feeding, which may have contributed to the
improvement in cholestasis. No adverse effects were relat-
ed to treatment with sincalide.
Currently, a randomized, placebo-controlled, double-
blind multicenter study is underway comparing the effects
of sincalide and placebo on conjugated bilirubin levels,
serum bile acid levels, and morbidity and mortality in pre-
mature neonates (birth weight <1000 g, estimated gesta-
tional age ≤28 wk). To better establish the short- and long-
term efficacy of sincalide on the development of biliary
sludge and biliary stone formation, this trial will also eval-
uate ultrasonographic images of the hepatobiliary tree dur-
ing and 1–2 years after administration of sincalide or
placebo.
SUMMARY
The majority of studies evaluating the clinical efficacy
and safety of sincalide in the treatment and prevention of
PNAC have been conducted in the pediatric population.
These studies have been generally small and uncontrolled.
In infants with PNAC, sincalide 0.04 µg/kg every 8 hours
appears to be generally well tolerated. The most common
adverse effect with sincalide is abdominal cramping that
appears to be dose related. No firm conclusion can be de-
rived as to the efficacy of sincalide in the prevention or
treatment of PN-associated gallbladder disease. Although
sincalide improves bile flow and the signs of PNAC, its
long-term effects in preventing sludge formation, chole-
lithiasis, and PNAC remain unknown. 
The best approaches to prevent PN-associated biliary
disease remain avoiding overfeeding, providing balanced
caloric intake, and most importantly, the early initiation of
oral or enteral feeding to maintain gut integrity and stimu-
late CCK secretion. Studies to date included a small num-
ber of patients and had a short-term follow-up. Evidence in
the form of large, prospective, randomized, placebo-con-
trolled, long-term follow-up studies is still needed to con-
firm the safety and efficacy of sincalide for the treatment
and prevention of PNAC.
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EXTRACTO
OBJETIVO: Evaluar el rol de sincalide en el tratamiento y prevención de la
enfermedad de la vesícula biliar asociada a la nutrición parenteral.
FUENTES DE INFORMACIÓN: Se realizó una búsqueda a través de
MEDLINE entre el período de enero de 1996 a marzo de 2004. Los
términos utilizados para la búsqueda fueron colecistocinina, sincalide,
nutrición parenteral, colelitiasis, colestasis, e impurezas.
SÍNTESIS: Cinco estudios en humanos investigaron la seguridad y eficacia
de sincalide en pacientes con enfermedad de la vesícula biliar asociada a
la nutrición parenteral.
CONCLUSIONES: Sincalide mejoró los signos de la colestasis. Sin
embargo, los efectos a largo plazo en el manejo y prevención de la
enfermedad de la vesícula biliar asociada a la nutrición parenteral aún se
desconocen por lo que su uso rutinario para esta indicación no puede ser
recomendado en este momento.
Mitchell Nazario
RÉSUMÉ
OBJECTIF: Revoir le rôle du sincalide dans le traitement et la prévention
de la maladie de la vésicule biliaire associée à l’alimentation parentérale.
SOURCES DE DONNÉES: Une revue de la documentation scientifique
MEDLINE (1996–mars 2004) a été réalisée utilisant les mots clés
cholécystokinine, sincalide, alimentation parentérale, lithiase biliaire,
cholestase, et agrégat.
SYNTHÈSE DES DONNÉES: Cinq études chez l’être humain ont examiné
l’efficacité et l’innocuité du sincalide chez les patients porteur d’une
maladie de la vésicule biliaire associée à l’alimentation parentérale.
CONCLUSIONS: Le sincalide améliore les signes de cholestase. Cependant,
ses effets à long terme dans la prévention et le traitement de la maladie
de la vésicule biliaire associée à l’alimentation parentérale demeurent
inconnus et son utilisation courante pour cette indication ne peut pas être
recommandée pour l’instant.
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